NASDAQ$MREO
Mereo Biopha-Adr · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Mereo BioPharma Group plc reported its full year 2024 financial results, highlighting progress in clinical trials and strategic advancements.
Mereo BioPharma reported a net loss of $43.3 million for the full year ended December 31, 2024, compared to a net loss of $29.5 million in 2023. The company's cash and cash equivalents stood at $69.8 million as of December 31, 2024, with operations expected to be funded into 2027.
- The Phase 3 Orbit study of setrusumab in osteogenesis imperfecta is progressing, with the second interim analysis expected mid-2025 and potential final analysis in Q4 2025.
- Alvelestat received Orphan Designation from the European Commission for the treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD).
- Total research and development expenses increased by $3.5 million to $20.9 million in 2024, driven by preparatory work for the Phase 3 study of alvelestat and ongoing activities for setrusumab.
- General and administrative expenses increased by $8.0 million to $26.4 million in 2024, primarily due to higher pre-commercial activities for setrusumab in Europe and increased corporate expenses.
Headline financials
Revenue & EPS history
Mereo Biopha-Adr · Revenue · Quarterly
$0
Forward guidance
Mereo BioPharma expects its existing cash and cash equivalents to fund its operations, clinical trials, and capital expenditure requirements into 2027. This guidance does not include potential upfront payments from new partnerships.
Tailwinds
- Existing cash and cash equivalents are expected to fund operations into 2027.
- The Phase 3 Orbit study of setrusumab is on track for second interim analysis mid-2025 and final analysis in Q4 2025.
- Pre-commercial activities for setrusumab in Europe are ongoing to prepare for launch.
- Alvelestat's European Orphan Designation and Phase 3 readiness activities are supportive of ongoing partnering discussions.
- The company anticipates a transformative 2025 focused on bringing therapies to patients.
Headwinds
- Guidance does not include potential upfront payments from new partnerships for alvelestat or non-core programs.
- Future developments affecting the company may differ from current anticipations.
- Reliance on third parties for clinical trials and funding introduces uncertainties.
- Dependence on patient enrollment in clinical trials poses a risk.
- The company's dependence on key executives is a factor to consider.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q4 2024
+3.4%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+17.3%
Avg return
30 days after
69%
9 / 13 earnings
Positive
+11.9%
Q4 2023
Best reaction
-6.1%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.1% | +0.9% | — | |
| Q4 2025 | +4.6% | -4.5% | -4.3% | |
| Q3 2025 | +6.3% | +0.6% | +27.1% | |
| Q2 2025 | +9.4% | +14.5% | +19.7% | |
| Q1 2025 | +1.3% | -2.2% | +25.3% | |
| Q4 2024 | -3.6% | -11.6% | +15.6% | |
| Q3 2023 | -5.4% | -17.5% | -12.9% | |
| Q3 2024 | -5.4% | -17.5% | -12.9% | |
| Q2 2024 | +6.2% | +16.4% | +18.0% | |
| Q1 2023 | +10.5% | +10.1% | +43.6% | |
| Q1 2024 | +10.5% | +10.1% | +43.6% | |
| Q4 2023 | +11.9% | +15.6% | -7.1% | |
| Q4 2022 | -6.1% | -10.3% | +52.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro